Bed bugs quail after exposure to Merck drug; Congress eyes compounding as FDA reports violations;

@FiercePharma: Israeli legal scholars move to sue Teva for shrouding details on executive pay. More | Follow @FiercePharma

> Merck's ($MRK) Stromectol, a treatment for parasitic worms, might be useful in controlling bed bugs, a study found. Report

> Congressional hearings will focus on the business practices of New England Compounding Center and on whether regulators did enough to police them. Report | More

> Belgium-based Arseus has bought three companies that supply ingredients to compounding pharmacies and plans to buy more this year, anticipating growth in the field. Report

> Watson Pharmaceuticals ($WPI) won FDA approval for its version of Pfizer's ($PFE) blood pressure drug Revatio. Report

> Germany's Boehringer Ingelheim plans to focus on its branded drugs, rather than branded generics, and on consumer health products for expansion in India. Report

Biotech News

 @FierceBiotech: Trending on FierceBiotech.com: 10 Top Women in Biotech 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: Alnylam to pay $75M to settle legal squabble over Tekmira's RNAi delivery tech. Story | Follow @JohnCFierce

 @RyanMFierce: $GILD is looking smart today for buying 7977. Market cap appears to have jumped $6.8B yesterday on news of its 100% SVR with hep C slayer. | Follow @RyanMFierce

> Fast-growing Gilead Sciences blueprints expansion, new R&D hires. News

> Pearl lands $65M round to fuel PhIII COPD showdown with Novartis, GSK. Story

Medical Device News

 @FierceMedDev: Chinese device maker Dehaier Medical saw Q3 revenue dip. The reason: an expansion strategy has yet to fully take hold. More | Follow @FierceMedDev

 @MarkHFierce: PerkinElmer snatched up an infectious disease Dx company based in China. More | Follow @MarkHFierce

 @DamianFierce: Hologic took a dive in the last quarter but predicts its $3.8B Gen-Probe buy will brighten the future. Story | Follow @DamianFierce

> Epic Sciences nabs $13M for cancer diagnostics. News

> China's Dehaier Medical Systems' Q3 stagnates as seeds planted for expansion. Report

Biotech Research News

> Harvard's microchip, lined with living cells, mimics disease in preclinical drug test. Report

> Stem cells produce the next potential Alzheimer's treatment. Item

> Kancera credits new drug with slowing pancreatic cancer tumor growth. Article

> Anti-inflammatory drugs that minimize infection risk appear possible. News

> Scientists crack genetic code for rare childhood leukemia variation. Story

Pharma Manufacturing News

> Lundbeck manufacturing starts small in China. Report

> Orchid closing up shop in China. More

> EFCG demands EU inspections of foreign API makers. Article

> FDA confirms Novartis plant, renewing CEO's confidence. Story

> Pilot shows national track and trace 'not insurmountable'. Editor's Corner

And Finally... If heartburn drugs don't work, it might not be the right kind of heartburn. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.